Literature DB >> 3067086

Clinical investigation in Duchenne muscular dystrophy: penicillamine and vitamin E.

G M Fenichel1, M H Brooke, R C Griggs, J R Mendell, J P Miller, R T Moxley, J H Park, M A Provine, J Florence, K K Kaiser.   

Abstract

A double-blind controlled trial of penicillamine and vitamin E against placebo was conducted in 106 boys with Duchenne muscular dystrophy. Nine dropped out of the study after being randomized. Patients were evaluated using an established protocol that measures muscle strength, joint contractures, functional grade, and pulmonary function. The trial lasted for 18 months. The power of the study to detect a 75% slowing of the disease was 0.95 at a P less than 0.05. No therapeutic effect was observed in the patients taking penicillamine and vitamin E as compared with those taking placebo.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3067086     DOI： 10.1002/mus.880111110

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


  9 in total

1.  Increased catalase expression improves muscle function in mdx mice.

Authors:  Joshua T Selsby
Journal:  Exp Physiol       Date:  2010-11-01       Impact factor: 2.969

Review 2.  Exacerbation of pathology by oxidative stress in respiratory and locomotor muscles with Duchenne muscular dystrophy.

Authors:  John M Lawler
Journal:  J Physiol       Date:  2011-03-08       Impact factor: 5.182

3.  Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy.

Authors:  Dennis J Matthews; Katherine A James; Lisa A Miller; Shree Pandya; Kimberly A Campbell; Emma Ciafaloni; Katherine D Mathews; Timothy M Miller; Christopher Cunniff; F John Meaney; Charlotte M Druschel; Paul A Romitti; Deborah J Fox
Journal:  J Child Neurol       Date:  2010-03-05       Impact factor: 1.987

Review 4.  Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.

Authors:  Luis Garegnani; Martin Hyland; Pablo Roson Rodriguez; Camila Micaela E Escobar Liquitay; Juan Va Franco
Journal:  Cochrane Database Syst Rev       Date:  2021-11-08

Review 5.  Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.

Authors:  Luis Garegnani; Martin Hyland; Pablo Roson Rodriguez; Camila Micaela Escobar Liquitay; Juan Va Franco
Journal:  Cochrane Database Syst Rev       Date:  2021-12-01

Review 6.  Contribution of oxidative stress to pathology in diaphragm and limb muscles with Duchenne muscular dystrophy.

Authors:  Jong-Hee Kim; Hyo-Bum Kwak; LaDora V Thompson; John M Lawler
Journal:  J Muscle Res Cell Motil       Date:  2012-10-28       Impact factor: 2.698

7.  (-)-Epicatechin improves mitochondrial-related protein levels and ameliorates oxidative stress in dystrophic δ-sarcoglycan null mouse striated muscle.

Authors:  Israel Ramirez-Sanchez; Sergio De los Santos; Silvia Gonzalez-Basurto; Patricia Canto; Patricia Mendoza-Lorenzo; Carlos Palma-Flores; Guillermo Ceballos-Reyes; Francisco Villarreal; Alejandro Zentella-Dehesa; Ramon Coral-Vazquez
Journal:  FEBS J       Date:  2014-10-30       Impact factor: 5.542

8.  Duchenne Muscular Dystrophy.

Authors:  Susan T. Iannaccone; Zohair Nanjiani
Journal:  Curr Treat Options Neurol       Date:  2001-03       Impact factor: 3.972

9.  Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: past, present, and future.

Authors:  Agnieszka Łoboda; Józef Dulak
Journal:  Pharmacol Rep       Date:  2020-07-20       Impact factor: 3.024
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.